📅 PUBMED DAILY TRIAGE — 2026-04-29

Window: 2026-04-28T09:00:00Z → 2026-04-29T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~95 candidates | Candidates evaluated: 16 scored High priority: 3 | Standard: 10 | Low/archive: 3 | Unsolicited finds: 0 Run status: PARTIAL_SUCCESS

🔴🟠 HIGH PRIORITY (score ≥8 or NOVEL_TREATMENT / EARLY_CANCER_DETECTION flag)

Rare Diseases with High Unmet Need

TR-2026-04-29-001 / PMID 42049986 · Excellent outcomes using novel RIC + post-transplant cyclophosphamide for HLA-matched related HSCT in adolescents and adults with sickle cell disease · 9/10 · 🟠 NOVEL_TREATMENT
Prospective multicenter study (N=25, median FU 42 months): 5-yr EFS 96%, 2-yr OS 100%, zero graft failures, grade III-IV acute GVHD only 4% — addresses critical unmet need for adult SCD patients where optimal conditioning has been undefined and outcomes inferior to pediatric cohorts.
Bone Marrow Transplantation · Alasbali R, Alzahrani M, Kassim AA, AlAhmari A et al. · doi:10.1038/s41409-026-02876-3

AI/ML in Clinical Diagnostics and Imaging

TR-2026-04-29-002 / PMID 42050390 · GPND-AI NULISA: A 15-Protein AI classifier for diagnosis and co-pathology profiling across neurodegenerative diseases · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
Plasma proteomic AI classifier achieving AUC 0.955, 92.3% accuracy across Alzheimer's, Parkinson's, FTD, and Lewy body dementia simultaneously, including co-pathology profiling; externally validated against neuropathology-confirmed diagnoses.
Alzheimer's & Dementia · Xu Y, Cruchaga C et al. (Washington University / Banner) · doi:10.1002/alz.71420

Novel Therapeutics: Targeted Therapy

TR-2026-04-29-003 / PMID 42050152 · The clinical landscape of HIF2α inhibitors in oncology · 7/10 + 🟠 NOVEL_TREATMENT
Nat Rev Clin Oncol review by Choueiri et al. (Dana-Farber/Harvard) synthesizing belzutifan's multiple FDA approvals (VHL disease, ccRCC, PHEO/PGL) + emerging agents (casdatifan, NKT2152, RNAi) + Phase 3 LITESPARK-011 data (belzutifan+lenvatinib vs cabozantinib); resistance mechanisms and on-target toxicity management.
Nature Reviews Clinical Oncology · Saad E, Machaalani M, McDermott DF, Choueiri TK · doi:10.1038/s41571-026-01145-y

🟢⚪ STANDARD (score 5–7) — Top by Topic

Hematologic Malignancies

• PMID 42050082 · BCMA-Targeted Bispecific Antibodies in RRMM: Three Approvals, Many Questions · 6/10 · Treatment Innovation
• PMID 42050342 · AID adverse prognostic significance in DLBCL/R-CHOP, N=70 · 5/10 · Diagnostics
• PMID 42050364 · OVCA2 oncogene in pediatric AML via CDKN1A repression (in vitro) · 5/10 · Drug Development
• PMID 42050093 · PRO-based outpatient follow-up for lymphoma/CLL (Danish prospective) · 5/10 · Public Health

Cardiovascular-Metabolic: SGLT2 / Cardiometabolic

• PMID 42049990 · SGLT2i weight change and prognosis in NSCLC+diabetes, N=82 retrospective · 5/10 · Public Health
• PMID 42050073 · Menopausal status impact on bone/body composition after bariatric surgery, 2-yr prospective · 5/10 · Public Health

Aging / Longevity / Immunosenescence

• PMID 42050386 · T cell immunosenescence in inflammatory skin diseases: pathogenesis and therapeutic targets (review, Aging Cell) · 5/10 · Treatment Innovation

Rare Diseases

• PMID 42044980 · CGM-guided cornstarch personalization in hepatic glycogen storage disease, N=32 · 5/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
• PMID 42044937 · Multidisciplinary management of XLMTM in Spain/Portugal, N=24 · 5/10 · 🟡 UNDERSERVED_POPULATION
• PMID 42044943 · FGF14 GAA expansion ataxia + aminopyridines, N=8, median 43-month follow-up · 5/10 · 🟢 NEAR_TERM_IMPLEMENTABLE

💡 UNSOLICITED FINDS

None this run. Off-watchlist items (capsule endoscopy 3D modeling, children's self-care DL, dental radiograph DL) scored <4 and discarded.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 6 (42049986, 42050152, 42050082, 42050386, 42044937, 42044943)
• Diagnostics: 4 (42050390, 42050342, 42050093, 42044980)
• Public Health: 4 (42049990, 42050073, 42050364, 42050093)
• Drug Development: 1 (42050364)
• Other/Exploratory: 1 (42049778)

By evidence maturity:

• Validated: 3 (42049986, 42050390, 42050152)
• Exploratory: 12

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed 16 | preprint 0

Topics with zero 8+ articles this run: Hematologic malignancies (standalone), Cardiometabolic, Aging/longevity, CBC/ML hematology, Precision oncology, Sentinel scan

🔧 RUN NOTES

• PARTIAL_SUCCESS: Abstract batch truncation (50KB limit) affected deep coverage of high-volume topics (AI/ML=114, Novel therapeutics=109, Aging=136, Sentinel=318). Top 10 candidates reviewed per topic where feasible.
• Deferred PMIDs processed this run: 10 of 20 deferred from 2026-04-28 (42044937, 42044943, 42044980, 42045051, 42045154, 42045422); 10 not yet reviewed (42045987–42045958 range) deferred again to 2026-04-30.
• CBC/ML hematology: sixth consecutive sparse CRDT window. 12 total raw results; top result (PMID 42050008, ALS transcriptomic ML classifier) was off-watchlist. Topic may require broader query (include "blood" + AI without CBC constraint) starting next run.
• Sentinel scan: 318 raw results; reviewed top 3 IDs (42050363, 42050356, 42050355); standard-range findings, no high-signal items identified.
• No rolling 7-day topic performance data available (state tracking shows individual PMIDs only, not per-topic streak counts; CBC/ML sparse streak noted in prior run notes).
• New HIGH article alert: PMID 42049986 (SCD HSCT) is exceptional — highest score this run (9/10).